Form 4 Tracker
Christopher Ryan Sullivan

Chief Financial Officer · 8 filings · Latest: Jun 10, 2026

Avalo Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
AVTX
Christopher Ryan SullivanChief Financial OfficerMay 7, 2026
Sale
$24.1218,606$448.8K423
AVTX
Christopher Ryan SullivanChief Financial OfficerMay 7, 2026
Option Exercise
$9.8818,606$183.8K19,029
AVTX
CHRISTOPHER SULLIVANMay 7, 2026
Proposed Sale
$21.8118,606$405.8K
AVTX
Christopher Ryan SullivanChief Financial OfficerMay 6, 2026
Sale
$20.1947,000$948.7K423
AVTX
Christopher Ryan SullivanChief Financial OfficerMay 6, 2026
Option Exercise
$8.0447,000$377.9K47,423
AVTX
CHRISTOPHER SULLIVANMay 6, 2026
Proposed Sale
$16.2647,000$764.2K
AVTX
Christopher Ryan SullivanChief Financial OfficerApr 30, 2026
Sale
$13.238,457$111.9K423
AVTX
Christopher Ryan SullivanChief Financial OfficerApr 29, 2026
Sale
$13.098,458$110.7K8,880
AVTX
CHRISTOPHER SULLIVANApr 29, 2026
Proposed Sale
$12.8616,915$217.5K
AVTX
Christopher Ryan SullivanChief Financial OfficerApr 2, 2026
Sale
$17.157,980$136.8K17,338
AVTX
Christopher Ryan SullivanChief Financial OfficerApr 1, 2026
Sale
$16.777,979$133.8K25,318
AVTX
CHRISTOPHER SULLIVANApr 1, 2026
Proposed Sale
$14.9315,959$238.3K
AVTX
Christopher Ryan SullivanChief Financial OfficerMar 28, 2026
Option Exercise
24,20041,538